Biocon Biologics Limited has acquired the Biosimilar business of Viatris Inc. for US$3.3 billion.

K Law advised and assisted Biocon with conducting vendor due diligence.

The transaction team consisted of Shwetambari Rao (Senior Partner), Puneet Prabhakar (Associate Partner), Tripti Sinha (counsel), Bharkavi S (Associate), Reuel Wilson (Associate), Sadia Akhter (Associate), Harshit Kumar (Associate).

The team was also assisted by Sandeep Kulkarni (Company Secretary) and Mallikarjun (Company Secretary).

With the transaction, Biocon will acquire Viatris' global commercial infrastructure in developed and emerging markets, as well as its global biosimilars business, which is expected to generate more than $1 billion in revenue next year, with an estimated $875 million in revenue and $200 million in EBITDA for CY 2022.

If you would like your Deals, Columns, Press Releases to be published on Bar & Bench, please fill in the form available here.